Tocqueville Asset Management’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-15,780
| Closed | -$2.84M | – | 849 |
|
|
2017
Q3 | $2.84M | Sell |
15,780
-10,525
| -40% | -$1.47M | 0.03% | 404 |
|
|
2017
Q2 | $2.73M | Sell |
26,305
-14,500
| -36% | -$1.18M | 0.03% | 382 |
|
|
2017
Q1 | $3.2M | Sell |
40,805
-17,160
| -30% | -$1.06M | 0.04% | 359 |
|
|
2016
Q4 | $2.6M | Buy |
57,965
+21,915
| +61% | +$1.08M | 0.03% | 377 |
|
|
2016
Q3 | $2.01M | Buy |
36,050
+1,800
| +5% | +$100K | 0.02% | 409 |
|
|
2016
Q2 | $1.71M | Sell |
34,250
-600
| -2% | -$29.5K | 0.02% | 438 |
|
|
2016
Q1 | $1.6M | Buy |
34,850
+11,300
| +48% | +$547K | 0.02% | 427 |
|
|
2015
Q4 | $1.45M | Sell |
23,550
-550
| -2% | -$38.7K | 0.02% | 469 |
|
|
2015
Q3 | $1.34M | Buy |
24,100
+2,450
| +11% | +$154K | 0.02% | 505 |
|
|
2015
Q2 | $1.32M | Sell |
21,650
-2,300
| -10% | -$131K | 0.02% | 522 |
|
|
2015
Q1 | $1.38M | Buy |
23,950
+9,250
| +63% | +$620K | 0.02% | 532 |
|
|
2014
Q4 | $848K | Buy |
+14,700
| New | +$619K | 0.01% | 608 |
|
Tocqueville Asset Management's KITE Position: Q4 2017 in Review
Tocqueville Asset Management sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 15,780 shares — an estimated $2.84M sold.
Tocqueville Asset Management first reported a position in KITE in Q4 2014 and held it in 12 quarters. The position peaked at $3.2M in Q1 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Tocqueville Asset Management reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Tocqueville Asset Management sold 15,780 Kite Pharma, Inc. shares in Q4 2017, an estimated $2.84M.
- Tocqueville Asset Management first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 12 quarters.
- Tocqueville Asset Management's Kite Pharma, Inc. position peaked at $3.2M in Q1 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Tocqueville Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.